Cilofexor

Cilofexor (GS-9674) is a potent, selective and orally active nonsteroidal FXR agonist with an EC50 of 43 nM. Cilofexor has anti-inflammatory and antifibrotic effects. Cilofexor has the potential for primary sclerosing cholangitis (PSC) and nonalcoholic steatohepatitis (NASH) research[1][2].

Product Specifications

CAS Number

[1418274-28-8]

Product Name Alternative

GS-9674

UNSPSC

12352005

Hazard Statement

H302, H312, H332

Target

Autophagy; FXR

Type

Reference compound

Related Pathways

Autophagy; Metabolic Enzyme/Protease

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Cilofexor.html

Purity

99.82

Solubility

DMSO : 50 mg/mL (ultrasonic)

Smiles

ClC1=C(C2(CN(C3=CC(C(O)=O)=CC=N3)C2)O)C=CC(OCC4=C(C5CC5)ON=C4C(C(Cl)=CC=C6)=C6Cl)=C1

Molecular Formula

C28H22Cl3N3O5

Molecular Weight

586.85

Precautions

H302, H312, H332

References & Citations

[1]Trauner M, et al. The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019 Sep;70 (3) :788-801.|[2]Patel K, et al. Cilofexor, a Nonsteroidal FXR Agonist, in Non-Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial. Hepatology. 2020 Mar 1.|[3]P. Schwab, et al. The FXR agonist GS-9674 reduces fibrosis and portal hypertension in a rat model of NASH. April 2018, Volume 68, Supplement 1, Pages S471-S472.